Radient Technologies Inc
XTSX:RTI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its Industry Average (15.5), the stock would be worth CA$-0.04 (803% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -2.2 | CA$0.01 |
0%
|
| Industry Average | 15.5 | CA$-0.04 |
-803%
|
| Country Average | 22 | CA$-0.05 |
-1 098%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
|
Radient Technologies Inc
XTSX:RTI
|
2.7m CAD | -2.2 | -0.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
804.2B USD | 59.5 | 39 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.4B USD | 21 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 27.5 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212.4B GBP | 50.6 | 27.5 | |
| CH |
|
Novartis AG
SIX:NOVN
|
220.1B CHF | 16.2 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
274.6B USD | 12.1 | 15 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -766.6 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 22.3 | 11.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.3B USD | 24.2 | 19.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.9B USD | 19.1 | 16.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.2 |
| Median | 22 |
| 70th Percentile | 36 |
| Max | 116 589.8 |
Other Multiples
Radient Technologies Inc
Glance View
Radient Technologies, Inc. engages in manufacture of natural ingredients in the food and beverage, nutrition and supplements, pharmaceuticals, and active care industries. The company is headquartered in Edmonton, Alberta. The company went IPO on 2011-08-24. The firm's principal activities are research, development and commercialization of technology for the extraction, isolation and purification of soluble products from a range of materials using microwave technology. The firm is focused on the formulation, manufacturing and launching of cannabis products. The company develops specialty products that contains a range of cannabinoid and terpene profiles. The company also operates a scientific and product testing laboratory that offers solutions to the cannabis and wellness spaces. Its extraction platform extracts cannabinoids from cannabis and hemp biomass. Its cannabis formulations include tinctures, topicals, sub-lingual sprays, standardized oils, stable water soluble and water dispersible powders and solid powders. Its cannabinoid-based ingredients are formulated for use in food and beverage products, personal care products and others.
